SCAN Targeted Epidural Modulation for Parkinson's Disease

The goal of this clinical trial is to learn if epidural modulation targeting the Somato-Cognitive Action Network (SCAN) can improve motor symptoms in adults with idiopathic Parkinson's disease (PD). It will also evaluate the safety of this treatment. The main questions it aims to answer are: * Does epidural modulation targeting SCAN reduce motor symptoms (measured by MDS-UPDRS-III scores) in PD patients after 3 months? * Is SCAN targeted epidural modulation (STEM) a safe and tolerable treatment for PD, with minimal adverse effects? Researchers will compare participants' baseline motor function to their post-treatment results to determine if STEM is effective. Participants will: * First undergo non-invasive brain stimulation (iTBS) to test responsiveness. * If eligible, receive surgical implantation of STEM electrodes in the personalized SCAN target. * Complete follow-up visits for 12 months to monitor symptoms, side effects, and quality of life.

NCT Number	NCT06919822
Lead Sponsor	Changping Laboratory Collaborators: First Affiliated Hospital of Fujian Medical University
Conditions	Parkinson Disease
Enrollment	3 participants
Start Date	2025-12-08
Primary Completion	2026-09 (estimated)
Study Completion	2027-05 (estimated)
Updated on ClinicalTrials.gov	2026-02-19